Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 100.36M shares outstanding
USShattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage.
Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases.
The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Abhinav Shukla, Ph.D.
Chief Technical Officer
Andrew R. Neill
Chief Financial Officer
Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B.
Chief Medical Officer
Casi DeYoung
Chief Business Officer
Employees
40
Country
US
Sector
Healthcare
Website
shattucklabs.com
Loading congressional disclosures…
based on 100.36M shares outstanding
US30d Avg
1.67M
60d Avg
1.20M
90d Avg
1.22M
